[{"data":1,"prerenderedAt":154},["ShallowReactive",2],{"drug-foscarnet":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":34,"contraindications":53,"warnings":63,"renal":71,"monitoring":72,"interactions":73,"review":74,"examples":77,"atc":78,"iran":80,"usApproval":96,"links":102,"populations":119},"foscarnet",1,{"fa":7,"en":8},"فوسکارنت","Foscarnet","anti-infectives",{"fa":11,"en":12},"ضدویروس (آنالوگ پیروفسفات)","Antiviral (pyrophosphate analogue)",[14],{"name":15,"market":16},"Foscavir","US",[18,19,7],"foscavir","فوسکاویر",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":29,"refs":30},"bot-24","injection","iv","24 mg\u002FmL (250 mL)",{"amount":27,"unit":28,"perVolumeMl":5},24,"mg",[16],[31],{"source":32,"section":33},"fda-foscavir","How Supplied",[35],{"id":36,"disease":37,"label":38,"population":41,"type":45,"unit":28,"dose":46,"refs":50},"cmv","cmv-infection",{"fa":39,"en":40},"رتینیت CMV — القا ۹۰ mg\u002Fkg هر ۱۲ ساعت یا ۶۰ mg\u002Fkg هر ۸ ساعت (۲ تا ۳ هفته)؛ نگهدارنده ۹۰ تا ۱۲۰ mg\u002Fkg\u002Fروز","CMV retinitis — induction 90 mg\u002Fkg every 12 h or 60 mg\u002Fkg every 8 h (2–3 weeks); maintenance 90–120 mg\u002Fkg\u002Fday",{"minAge":42},{"value":43,"unit":44},18,"year","notCalculated",{"reason":47},{"fa":48,"en":49},"برچسب: همه دوزها باید بر اساس عملکرد کلیه فردی شوند (جدول برچسب)؛ فقط با پمپ انفوزیون، هرگز بولوس؛ هیدراتاسیون پیش و حین درمان. HSV مقاوم به آسیکلوویر: ۴۰ mg\u002Fkg هر ۸ یا ۱۲ ساعت ۲ تا ۳ هفته.","Label: every dose must be individualised to renal function (label table); infusion pump only, never bolus; hydrate before and during. Aciclovir-resistant HSV: 40 mg\u002Fkg every 8 or 12 h for 2–3 weeks.",[51],{"source":32,"section":52},"Dosage and Administration",[54],{"id":55,"severity":56,"text":57,"refs":60},"hyper","block",{"fa":58,"en":59},"حساسیت قابل‌توجه به فوسکارنت.","Clinically significant hypersensitivity to foscarnet.",[61],{"source":32,"section":62},"Contraindications",[64],{"text":65,"refs":68},{"fa":66,"en":67},"هشدار جعبه‌ای: نارسایی کلیه (شایع‌ترین عارضه محدودکننده)؛ اختلال مواد معدنی و الکترولیت (کلسیم، منیزیم) و تشنج.","Boxed warning: renal impairment (major dose-limiting toxicity); mineral\u002Felectrolyte disturbances (calcium, magnesium) and seizures.",[69],{"source":32,"section":70},"Boxed Warning",[],[],[],{"status":75,"reviewer":76,"date":76},"unverified",null,[],[79],"J05AD01",{"status":81,"forms":82,"refs":91},"registered",[83,87],{"code":84,"en":85,"fa":86},"07111","FOSCARNET 24MG\u002FML 250ML INJ","فرآورده تزریقی فوسکارنت ۲۴ میلی‌گرم \u002F میلی‌لیتر ۲۵۰ میلی‌لیتر",{"code":88,"en":89,"fa":90},"52426","FOSCARNET SODIUM INJECTION, SOLUTION PARENTERAL 24 mg\u002F1mL 250 mL","محلول تزریقی فوسکارنت سدیم ۲۴ میلی‌گرم \u002F ۱ میلی‌لیتر ۲۵۰ میلی‌لیتر",[92],{"source":93,"section":94,"url":95},"darooyab-generic","G-1176\u002FFoscarnet","https:\u002F\u002Fwww.darooyab.ir\u002FG-1176\u002FFoscarnet",{"kind":97,"refs":98,"id":101},"NDA",[99],{"source":32,"section":100},"SPL approval \u002F marketing category","NDA020068",[103,106,110,114,117],{"kind":104,"url":105,"label":101},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=020068",{"kind":107,"url":108,"label":109},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=90e3da4e-3b1f-428b-99ca-e4bed1c80028","FDA Foscavir",{"kind":111,"url":112,"label":113},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa601144.html","Foscarnet Injection",{"kind":115,"url":116,"label":79},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J05AD01",{"kind":118,"url":95,"label":8},"darooyab",{"pregnancy":120,"lactation":129,"pediatric":137,"geriatric":146},{"level":121,"text":122,"quote":125,"refs":126},"caution",{"fa":123,"en":124},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.",[127],{"source":32,"section":128},"Pregnancy",{"level":121,"text":130,"quote":133,"refs":134},{"fa":131,"en":132},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Because of the potential for serious adverse events in nursing infants, a decision should be made whether to discontinue nursing or discontinue drug, taking into consideration the importance of the drug to the mother.",[135],{"source":32,"section":136},"Nursing Mothers",{"level":138,"text":139,"quote":142,"refs":143},"not-established",{"fa":140,"en":141},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","The safety and effectiveness of FOSCAVIR in pediatric patients have not been established.",[144],{"source":32,"section":145},"Pediatric Use",{"level":121,"text":147,"quote":150,"refs":151},{"fa":148,"en":149},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored.",[152],{"source":32,"section":153},"Geriatric Use",1792191545681]